ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1497

Type I Interferon Status and Clinical Manifestations in a Large Cohort of Patients with Systemic Lupus Erythematosus
Abstract Number: 1416

Ultrasound (US)-guided Core-needle Biopsy (CNB) of the Non-swollen Parotid Gland: A Feasible and Well-tolerated Technique for Diagnosing and Stratifying Sjögren’s Disease (SjD)
Abstract Number: 1639

Ultrasound Fast-Track Giant Cell Arteritis Clinic Experience in the United States
Abstract Number: 2073

Ultrasound Findings of Activity in Patients with Inflammatory Myopathies and Clinical and Laboratory Comparison
Abstract Number: 1955

Ultrasound for Screening of Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review and Meta Analysis
Abstract Number: 0220

Ultrasound-assessed Dactylitis as a Biomarker in the Early Diagnosis of Psoriatic Arthritis
Abstract Number: 1193

Ultrasound-Guided Corticosteroid Injection versus Iontophoresis in Rhizarthrosis: A Prospective Comparative Multicentric Study
Abstract Number: 2290

Umbilical Cord-derived Mesenchymal Stem Cells Suppress Sjogren’s Syndrome Pathology
Abstract Number: 1852

Uncovering a MAIT-Treg Axis in Skin UV Response: Implications for Photosensitive Reactions in Cutaneous Lupus Erythematosus
Abstract Number: 0893

Uncovering Common and Distinctive Molecular Profiles Between Early and Stablished Rheumatoid Arthritis Through Integrative Multi-omics Analysis and Its Association with Disease Status and Clinical Response
Abstract Number: 2190

Uncovering Inborn Errors of Immunity in Pediatric Rheumatology
Abstract Number: 0126

Underdiagnosis Prediction Fingerprint for Antiphospholipid Syndrome Derived from Electronic Health Record Data
Abstract Number: 1985

Underlying Autoimmune Disease Has Not Limited Immune Checkpoint Inhibitor Use or Increased Mortality Risk During Cancer Treatment of US Veterans
Abstract Number: 1814

Understanding Monocyte Derived Macrophages in the Skin of SSc Patients Through Single Cell Analysis of Blister Fluid Immune Cell Populations
Abstract Number: 2079

Understanding Relapse Patterns in Anti-HMGCR Statin-induced IMNM: A Detailed Comparative Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].